Sickle cell disease disproportionately affects babies in Africa, but many go undiagnosed due to lack of screening. Newborn screening is needed to save lives and improve care.

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.